Apremilast news

All news on Apremilast (also known as Otezla): plants, production capacities, investments and involved companies.

28 May 2026

Johnson & Johnson: FDA approves TREMFYA label update for PsA joint‑damage inhibition

APEX Phase‑3b: in biologic‑naïve PsA patients, 24‑week results met ACR20 and significantly inhibited structural joint damage vs placebo; placebo switchers had 57% less radiographic progression to Week 48; safety unchanged.
4 May 2026

Amgen invests $300M more in U.S. manufacturing, nearly $2B over past year

Expands Puerto Rico biologics facility to boost U.S. production, deploy next‑gen technologies, support workforce development and construction jobs, and strengthen medicine supply‑chain resilience
22 April 2026

Amgen EVP & CTO David M. Reese to retire

Reese retires June 30, 2026. Effective June 1, leadership reshuffle: James Bradner named EVP R&D, AI & Data; Sean Bruich CTO; Murdo Gordon EVP Global Markets & Policy; Paul Burton remains CMO.

Who will be producing Apremilast in the future?

Find out with chemXplore Alpha

Learn more